A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States
Authors:
- 1 March 2021
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 223, 405-429
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2020
- Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular DegenerationOphthalmology, 2016
- Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue in Health, 2014
- Intravitreal Aflibercept Injection for Neovascular Age-related Macular DegenerationOphthalmology, 2014
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationOphthalmology, 2012
- Budget impact analysis in economic evaluation: a proposal for a clearer definitionThe European Journal of Health Economics, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006